SHC — Sotera Health Company

Sotera Health Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Full Year 2025 Results:

  • Total Revenue: $1.164 billion (up 5.7% YoY; 5.2% growth in constant currency)
  • Adjusted EBITDA: $593.8 million (up 8.2%; adjusted EBITDA margin at 51%, up 118 basis points)
  • Adjusted Free Cash Flow: Over $200 million
  • Net Income: $78 million ($0.27 per diluted share)
  • Adjusted EPS: $0.86 (up $0.16 YoY)

• Q4 2025 Results:

  • Total Revenue: $303 million (up 4.6%; 2.5% growth in constant currency)
  • Adjusted EBITDA: $157 million (up 2.7%; adjusted EBITDA margin at 51.8%)
  • Net Income: $35 million ($0.12 per diluted share)
  • Adjusted EPS: $0.26 (up $0.05 YoY)

2. Strategic Updates and Business Highlights

• Customer Satisfaction: Exceeded 80%, reflecting strong service commitment.
• Segment Performance:
  • Sterigenics: Revenue up 10.6% to $198 million, driven by pricing and volume.
  • Nordion: Revenue down 12.3% to $50 million due to Cobalt-60 harvest timing.
  • Nelson Labs: Revenue increased 2.3% to $55 million, impacted by lower Expert Advisory Services revenue.
• Capital Management:
  • Reduced borrowing costs by 75 basis points on a $1.4 billion term loan.
  • Paid down $86 million in debt, resulting in $13 million annual interest savings.
  • Liquidity improved with a $175 million increase in revolver capacity.
• Governance: Appointed Richard Kyle to the Board and promoted Erika Ostrowski to Senior Vice President and General Counsel.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected to be in the range of $1.233 billion to $1.251 billion (5% to 6.5% constant currency growth).
• Adjusted EBITDA Guidance: Projected between $632 million to $641 million (5.5% to 7% constant currency growth).
• Segment Expectations:
  • Sterigenics: Mid- to high single-digit constant currency revenue growth.
  • Nordion: Low to mid-single-digit constant currency revenue growth.
  • Nelson Labs: Low single-digit constant currency revenue growth.
• CapEx for 2026: Expected to be between $175 million to $225 million.

4. Bad News, Challenges, or Points of Concern

• Nordion Segment Challenges: Revenue decline attributed to Cobalt-60 harvest timing, which is expected to impact volumes.
• Sterigenics Commercial Segment: Noted as a challenging area with some customers reducing volumes and redesigning products post-COVID.
• Nelson Labs: Experienced headwinds from lower Expert Advisory Services revenue, which is expected to ease but remains a concern.
• Market Dynamics: Competitive pressures in Sterigenics due to extended compliance timelines for NESHAP regulations, leading to slower decision-making from customers regarding outsourcing.

5. Notable Q&A Insights

• Volume and Pricing Dynamics: Management indicated that volume and mix would drive performance towards the higher end of guidance.
• Sterigenics Outsourcing Trends: While some customers are transitioning back to outsourcing sterilization, the urgency has decreased due to regulatory extensions.
• Nelson Labs Margins: Expected to remain in the low to mid-30% range, with Q1 typically being the weakest quarter.
• CapEx and Growth Strategy: Continued focus on organic investments and maintaining cash flow targets, with no immediate plans for acquisitions.
• Competitive Landscape: Sterigenics remains well-positioned despite challenges, with strong customer satisfaction and a robust service model.

Overall, Sotera Health demonstrated solid financial performance in 2025, with a positive outlook for 2026, although certain segments face challenges that could impact growth.